Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281533 | 0.98 | BACE1 (0.71) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8279670 | 0.93 | BACE1 (0.63) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8280713 | 0.91 | BACE1 (0.70) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14433489 | 0.87 | BACE1 (0.58) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8281540 | 0.87 | BACE1 (0.78) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6544448 | 0.86 | BACE1 (0.56) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8280835 | 0.84 | BACE1 (1.00) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8280899 | 0.84 | BACE1 (0.74) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8280834 | 0.84 | BACE1 (0.74) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8282517 | 0.84 | BACE1 (0.74) | BACE1ALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | SCHMITZ FRANZ ULRICH | 2010-01-07 | — | — | US | disclosed |
| US-7595398-B2 | N-(5-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| CN-101331125-A | N-(5-membered aromatic ring)-amido anti-viral compounds | GENELABS TECH INC (US) | 2008-12-24 | — | — | CN | disclosed |
| EP-1971597-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-30 | — | — | US | disclosed |
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-30 | — | — | US | disclosed |
| WO-2007070600-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2005097767-A1 | 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYL PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203147-A1 | 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors | BACE2, BACE1, APP | BACE1 2/4885ALDH1A1 1717/4885SMN1; SMN2 2512/4885 |
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, HAVCR2 | BACE1 1358/4885ALDH1A1 4423/4885SMN1; SMN2 1431/4885 |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, HAVCR2 | BACE1 1358/4885ALDH1A1 4423/4885SMN1; SMN2 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.